-
Press Release
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
-
Press Release
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
-
Press Release
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
-
Story
Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond -
Press Release
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
-
Press Release
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
-
Press Release
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
-
Press Release
Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt
-
Press Release
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
-
Press Release
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
-
Press Release
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
-
Press Release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030